

Cancer - Nivolumab Treatments

Reference Number: RDF2169-23

Date of Response: 29/12/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Q1. In the last 3 months, how many patients have been initiated on the following agents for the treatment of melanoma?*

Answer: Please see table below:

Agent	East	North	Total
Ipilimumab	≤5	0	≤5
Nivolumab	≤5	≤5	≤5
Nivolumab AND Ipilimumab	17	≤5	21
Pembrolizumab	19	8	27
Any Targeted Therapy	15	≤5	18
Other SACT	≤5	0	≤5

Please note the figures provided are for the latest 3 months available: August 2023 to October 2023.

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases, ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

Q2. In the last 3 months, how many patients have been initiated on the following agents for the treatment of Renal cell carcinoma?*

Answer: Please see table below:

Agent	East	North	Total
Nivolumab	≤5	≤5	≤5
Nivolumab + Ipilimumab	≤5	≤5	≤5
Nivolumab + Cabozantinib	0	0	0
Avelumab + Axitinib	0	0	0

Q3. In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer?

Answer: Please see table below:

Agent	East	North	Total
Nivolumab monotherapy or in combination with Ipilimumab	≤5	0	≤5
Nivolumab in combination with Platinum and Fluoropyrimide	0	0	0
Pembroliz in combination with Platinum and Fluoropyrimide	0	0	0

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*